Charles Ryan, MD

Associate Clinical Professor, Department of Medicine (Hematology/Oncology), UCSF

Phone: (415) 353-7171 (appts, urology); (415) 885-3882 (appts, thoracic)
Box 1711, UCSF
San Francisco, CA 94143-1711

View on UCSF Profiles

Additional Websites

• Physician Referral Directory

Education

Marquette University, BA, 1991, Philosophy
University of Wisconsin - Madison, MD, 1996, Medicine
University of Wisconsin Hospital and Clinics, 1996-97, Intern, Medicine
University of Wisconsin Hospital and Clinics, 1997-99, Resident, Medicine
University of Wisconsin Hospital and Clinics, 1999-00, Chief Resident, Medicine
Memorial Sloan-Kettering Cancer Center, 2000-03, Fellow, Medical Oncology

Professional Experience

• 2003-2008
  Assistant Clinical Professor of Medicine, University of California, San Francisco, CA
• 2008-present
  Associate Clinical Professor of Medicine, University of California, San Francisco, CA

Honors & Awards

• 1991
  Alpha Sigma Nu, National Jesuit University Academic Honor Society
• 1991
  Phi Beta Kappa, Marquette University
• 1994
  Leadership and Service Award, University of Wisconsin Medical School
• 1996
  John Kimberly Curtis Award, University of Wisconsin Medical School
• 2000
  Evergreen Award, American College of Physicians-American Society of Internal Medicine
• 2002
  ASCO Merit Award
• 2002
  Cancer And Leukemia Group B Young Investigator Award
• 2006
  Prostate Cancer Foundation: Donald Coffey Career Development Award
• 2007
  California Coalition to Cure Prostate Cancer Award

Selected Publications

1. Ryan CJ, Molina A, Griffin T. Abiraterone in metastatic prostate cancer. N Engl J Med. 2013 Apr 11; 368(15):1458-9.
   View on PubMed
2. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10; 368(2):138-48.
   View on PubMed
3. Ryan CJ, Cheng ML. Abiraterone acetate for the treatment of prostate cancer. Expert Opin Pharmacother. 2013 Jan; 14(1):91-6.
   View on PubMed
4. Ryan CJ, Rosenthal M, Ng S, Alumkal J, Picus J, Gravis G, Fizazi K, Forget F, Machiels JP, Srinivas S, Zhu M, Tang R, Oliner KS, Jiang Y, Loh E, Dubey S, Gerritsen WR. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res. 2013 Jan 1; 19(1):215-24.
   View on PubMed
5. Friedlander TW, Ryan CJ. Targeting the androgen receptor. Urol Clin North Am. 2012 Nov; 39(4):453-64.
   View on PubMed
6. Ryan CJ. Abiraterone: current and future use in prostate cancer. Clin Adv Hematol Oncol. 2012 Mar; 10(3):180-1.
   View on PubMed
7. Magbanua MJ, Sosa EV, Scott JH, Simko J, Collins C, Pinkel D, Ryan CJ, Park JW. Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer. BMC Cancer. 2012; 12:78.
   View on PubMed
8. Friedlander TW, Roy R, Tomlins SA, Ngo VT, Kobayashi Y, Azameera A, Rubin MA, Pienta KJ, Chinnaiyan A, Ittmann MM, Ryan CJ, Paris PL. Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res. 2012 Feb 1; 72(3):616-25.
   View on PubMed
9. Bryce A, Ryan CJ. Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor. Clin Pharmacol Ther. 2012 Jan; 91(1):101-8.
   View on PubMed
10. Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes GR, Jonasch E, Josephson D, Kuzel TM, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Spiess PE, Wang J, Wilder RB. Kidney cancer. J Natl Compr Canc Netw. 2011 Sep 1; 9(9):960-77.
    View on PubMed
11. Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol. 2011 Sep 20; 29(27):3651-8.
    View on PubMed
12. Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A, Small EJ. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011 Jul 15; 17(14):4854-61.
    View on PubMed
13. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26; 364(21):1995-2005.
    View on PubMed
14. Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer. 2011 Sep 15; 117(18):4194-200.
    View on PubMed
15. Aggarwal R, Ryan CJ. Castration-resistant prostate cancer: targeted therapies and individualized treatment. Oncologist. 2011; 16(3):264-75.
    View on PubMed
16. Friedlander TW, Ryan CJ. Editorial comment. J Urol. 2010 Nov; 184(5):1976.
    View on PubMed
17. Ryan C. Abiraterone in prostate cancer. Clin Adv Hematol Oncol. 2010 Nov; 8(11):761-2.
    View on PubMed
18. Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study. Urol Oncol. 2012 Jul-Aug; 30(4):408-14.
    View on PubMed
19. Beer TM, Ryan C, Alumkal J, Ryan CW, Sun J, Eilers KM. A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Anticancer Drugs. 2010 Apr; 21(4):433-8.
    View on PubMed
20. Shah S, Ryan C. Abiraterone acetate for castration resistant prostate cancer. Expert Opin Investig Drugs. 2010 Apr; 19(4):563-70.
    View on PubMed

View on UCSF Profiles